Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Lindner, C; Dierneder, J; Pall, G; Pirich, C; Hoffmann, M; Raderer, M; Becherer, A; Niederle, B; Lipp, R; Lind, P; Gallowitsch, H; Romeder, F; Virgolini, I.
[Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
Nuklearmedizin. 2015; 54(3):125-130
Doi: 10.3413/Nukmed-0688-14-07
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Lipp Rainer
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- There is no clear standard therapy for patients with radioactive iodine (131I)-refractory locally advanced or metastatic differentiated thyroid cancer. The therapeutic options for this indication have expanded with the recently approved multiple kinase inhibitor sorafenib. Recommendations for the definition and the management of iodine refractory patients were worked up by an interdisciplinary expert panel, consisting of endocrine surgeons, medical oncologists and nuclear medicine specialists.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Agents - administration & dosage
- Antineoplastic Agents - adverse effects
- Chemoradiotherapy - standards
- Evidence-Based Medicine -
- Germany -
- Humans -
- Iodine Radioisotopes - therapeutic use
- Medical Oncology - standards
- Niacinamide - administration & dosage
- Niacinamide - adverse effects
- Niacinamide - analogs & derivatives
- Phenylurea Compounds - administration & dosage
- Phenylurea Compounds - adverse effects
- Practice Guidelines as Topic -
- Protein Kinase Inhibitors - administration & dosage
- Protein Kinase Inhibitors - adverse effects
- Radiopharmaceuticals - therapeutic use
- Sorafenib -
- Thyroid Neoplasms - diagnosis
- Thyroid Neoplasms - therapy
- Treatment Failure -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Radioactive iodine-refractoriness
- sorafenib
- thyroid cancer